How much funding has Tikva Allocell raised?

Tikva Allocell has raised $8.0M in total funding, most recently a Series A round.

When was Tikva Allocell founded?

Tikva Allocell was founded in 2023.

Where is Tikva Allocell headquartered?

Tikva Allocell is headquartered in Singapore, Singapore.

What industry is Tikva Allocell in?

Tikva Allocell operates in Biotech, Healthcare, Therapeutics.

How many employees does Tikva Allocell have?

Tikva Allocell has 11-50 employees.

Tikva Allocell

Singapore, Singapore · Founded 2023 · $8.0M raised

Biotech

Healthcare

Therapeutics

Headquarters: Singapore
Employees: 11–50
Founded: 2023
Business Model: B2B

Website: tikvaallocell.com
Total Funding: $8.0M
Last Round: $8.0M Series AJul 2026
Rounds: 1

About

Tikva Allocell is a Singapore-based late-preclinical-stage cell therapy company developing allogeneic, off-the-shelf T cell therapies for solid tumors. Founded in 2023, the company's platform centers on a second-generation Allogeneic EBV-Specific T cell (ALLO EBVST) technology, which leverages donor-derived EBV-specific T cells enhanced with SerpinB9 (CAS) and engineered with a B7-H3 chimeric antigen receptor to overcome host immune rejection and persist long enough to attack solid tumors. Its lead program, TAVST01, targets B7-H3-positive cancers including lung, breast, prostate, pancreatic, and pediatric cancers. The company raised $8 million in Series A financing in July 2026, led by Kantharos Capital, to complete IND-enabling studies and initiate Phase 1 clinical trials in Singapore and the United States.

Summary

Tikva Allocell is a Biotech company based in Singapore, Singapore, founded in 2023. It has raised $8.0M in total across 1 round, most recently a $8.0M Series A round in Jul 2026.